Newton biotech gets $200M for rare muscle disease drug
Abcuro Inc. has raised a $200 million Series C financing to fund late-stage development and support commercial launch ...
rheumatologyadvisor3d
FDA Extends Review of Elamipretide for Barth Syndrome
The FDA has extended the review period for the New Drug Application for elamipretide for the treatment of Barth syndrome.
Healio4d
Silica dust, heavy metal, solvents may contribute to myositis with lung involvement
Exposures to silica dust, solvents or heavy metals increase the likelihood of developing various forms of myositis, ...